Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Manufacturability challenges in biotech are becoming more complex as therapies become more potent, formats diversify, and timelines compress across the industry. On this episode, David Brühlmann sits down with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. Sigma brings deep expertise in early-stage CMC decision-making and has guided countless programs—from upstart startups to established pipelines—through the traps and trade-offs of process development. Her ground-floor perspective spans in silico modeling, innovative cell line engineering, and the gritty realities of tech transfer. Key topics discussed: Practical advice for startups on selecting robust cell lines and avoiding long-term lock-in to problematic platforms (03:07) Managing risks in process development, such as high oxygen demand and filter loading, before tech transfer to manufacturing (04:47) The value of pressure testing bioprocesses at scale and identifying potential failure modes, including filter clogging and narrow feeding windows (07:41) Balancing speed, robustness, and regulatory expectations when advancing new molecules (09:23) How fast-tracking from transfection to IND is changing timelines, and the associated risks of accelerated development (09:54) Trends and caution in applying AI and in silico tools to protein and process modeling, and the limits of digital solutions (12:01) What first-time founders need to get right, including early analysis of molecular issues and careful cell line selection (15:48) Shifting modality trends—growing numbers of ADCs/XDCs, more complexity, and the move toward smaller scale and more potent molecules (16:55) The overarching lesson: invest early in the areas you cannot change later—especially cell line and understanding of molecule challenges (18:23) Smart insight: Startup founders often wonder which fires to fight first. Sigma’s advice: focus on deep molecular assessment and making informed, scalable cell line choices above all else. These are the “few things you cannot change later” and the investments that separate enduring programs from cautionary tales. This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent. Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa Connect with Sigma Mostafa: Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and process development get kicked down the road. On the Smart Biotech Scientist Podcast, David Brühlmann spoke with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. She’s spent 25+ years converting early-stage discoveries into commercial biomanufacturing success and she’s adamant: manufacturability decisions belong at the candidate selection stage, not after. Topics discussed: Why manufacturability should be assessed at the candidate selection stage, not later (03:02) Sigma’s background in bringing math and biology together and her path into bioprocess engineering (04:18) The "art" and complexity of bioprocess development, especially with new molecule types (05:54) A case study of how switching cell lines revealed hidden manufacturability issues (07:33) Key properties affecting manufacturability, such as aggregation and thermal stability (10:10) Reasons companies delay manufacturability assessments—timing pressure, costs, and lack of early deep characterization (11:02) Why CMC should be integrated from day one and concerns with treating scalability as 'just' engineering (12:08) Critical decisions and pitfalls in cell line development, including robustness, media choices, and adapting after the master cell bank is made (12:48) Regulatory aspects of cell line development: demonstrating clonality, avoiding animal source materials, and documentation requirements (15:04) Smart insight: Manufacturability is not just a box for the CMC team. It’s a proactive mindset, to be embraced from day one. Early, cross-functional scrutiny—examining both molecule and cell line—preempts disasters during scale-up and accelerates timelines to market while minimizing costly surprises. This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent. Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa Connect with Sigma Mostafa: Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications. Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has made a career out of asking impossible questions about glycosylation, cell line selection, and the hidden machinery at work inside every productive cell. He’s moved beyond academic curiosity—translating discoveries into applications and even launching a company, Augment Biologics, that’s taking glycoengineering from theory to practice. Topics discussed: A proximity proteomics approach to identify supporting machinery for challenging-to-express proteins like rituximab (02:36) Findings from expressing the full human secretome in CHO cells, and the correlation between host cell gene expression and protein productivity (05:00) Clarifying when host cell characteristics matter more than the protein construct itself (05:46) Emerging evidence that protein sequence and structure influence glycosylation patterns (contrary to previous dogma) (06:49) Engineering point mutations to precisely tune glycan features for improved therapeutic efficacy (09:25) The vision and activities of Augment Biologics in custom glycosylation control for drug discovery (10:32) The importance and barriers to open data sharing in bioprocessing, and thoughts on overcoming them (11:11) The shifting landscape as technology advances and the need for high-quality, annotated data (13:54) If this got you thinking about the data already sitting in your freezer, and what it would take to actually use it, start here. These four conversations dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all. Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty Connect with Nathan Lewis: Website: www.lewislab.uga.edu LinkedIn: www.linkedin.com/in/nathanelewis Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs. Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, and AI as a true scientific collaborator. Topics discussed: Rethinking the dogma: controlling protein glycosylation quality from the inside out, not just by bioprocess conditions (03:00) Nathan Lewis’s journey into science and bioprocessing, from unexpected college choices to pivotal advances in CHO cell engineering (05:12) The evolution of omics in bioprocessing: why actionable insights, not just big datasets, should be the goal (10:49) Strategic advice for structuring, annotating, and making old and new datasets ready for AI and LLM analysis (17:34) The balance between mechanistic and machine learning models—when each makes sense, and why hybrid modeling is gaining ground (22:20) The current and future role of digital twins in process development and why foundation models and data consortia matter for scalability (26:24) Smart insight: The real revolution isn’t in making new data, but in unlocking the value of what already exists. Advances in AI, hybrid modeling, and collaborative standards promise to turn decades-old data into a catalyst for innovation—enabling faster, smarter, and more reliable bioprocess development. If this got you thinking about the data already sitting in your freezer — and what it would take to actually use it — start here. These four dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all. Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty Connect with Nathan Lewis: Website: www.lewislab.uga.edu LinkedIn: www.linkedin.com/in/nathanelewis Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

“Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true. In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Hopkins postdoc project to a company with its first paying customer. In this episode: Common pushbacks and questions from industry regarding new cell line development technologies (03:18) Practical advice for resource-constrained startups developing cell lines, emphasizing efficiency and data quality over brute force automation (08:42) The role and value of DNA barcoding in screening and developing robust cell lines for therapeutics (08:56) Lessons learned from translating scientific innovation into a commercial product, including securing early support and customer trust (10:27) Insights on adapting messaging, leveraging feedback, and understanding market needs as part of the entrepreneurial process (13:52) Key differences between academic research and industry requirements for reliable, repeatable biotech tools (15:26) Kent’s most important takeaway for successful cell line development: focus on collecting the right data at the right scale for informed decisions (17:14) Smart insight: Translating innovations from academia to industry brings a new wave of challenges. Kent describes the “valley of death” separating a publishable prototype from a reliable, commercial-grade product. Academic success is often tied to novelty, publications, and grants, while industry demands repeatability, robustness, and consistent performance across labs and operators. Securing early champions and funding, iterating based on tough industry feedback, and building trust with initial partners all require resilience, and a willingness to pivot as needed. Feedback, even when harsh, becomes a “gift” that helps refine the product and business model. The secret is not a single breakthrough, but adaptability and relentless customer focus. If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up. Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti Connect with Kent Rapp: LinkedIn: www.linkedin.com/in/kent-rapp Biolinco website: www.biolinco.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them? Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies. This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of Biolinco, an entrepreneur who’s turning the classic approach to cell line development inside out. Drawing from his background in chemical engineering and his work in biomanufacturing at Johns Hopkins University, Kent teamed up with DNA barcoding experts to pioneer a new workflow: barcode every cell, pool them, and track their true performance in the environment that matters. Topics discussed: The pitfalls of brute-force screening in traditional cell line development (03:05) Kent’s background and how he was drawn to combine science, startups, and biomanufacturing (04:37) Overcoming discrepancies between small-scale and large-scale screening environments (08:30) How DNA barcoding allows for high-resolution, pooled clone screening (10:34) Sensitivity advantages of sequencing over plate-based detection (14:21) Methodology for tracking and recovering individual high-performing clones from pools (15:13) Impact on speed and workflow efficiency in cell line development (17:31) Regulatory and safety considerations related to DNA barcodes in cell lines (19:04) Smart insight: According to Kent, biotech as an industry has a tendency to "automate problems instead of solve them". Rather than addressing the root causes—like lack of meaningful measurements at relevant scales—companies often throw more robots and more plates at the issue, hoping brute force will finally yield the magical clone. But real process improvement requires a rethinking of what is being measured and how those insights are generated—not just a higher throughput of the same flawed assay. If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up. Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti Connect with Kent Rapp: LinkedIn: www.linkedin.com/in/kent-rapp Biolinco website: www.biolinco.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because that protein sits on the particle surface, and a component nobody has filed before is the agency's problem regardless of what you call it. Proteolipid vehicles (PLVs), the platform Jitendra Kumar works on as Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, represent a novel frontier in drug delivery, Instead of being taken up into an endosome and having to escape it, a PLV fuses with the cell membrane and releases cargo straight into the cytosol. That opens targets and patient groups that liver-tropic lipid nanoparticles and viral vectors have struggled to reach, and it leaves Kumar building a regulatory file with nothing on the shelf to copy. Highlights from the episode: Strategies for communicating novel technology with regulatory agencies and ensuring robust science-driven submissions (02:34) What differentiates the analytical characterization of PLVs compared to standard recombinant proteins or antibodies (04:03) The development plan and regulatory pathway towards clinical and commercial approval for their lead leptin therapy (05:35) The evolving role of advanced techniques—such as cryo-EM—in supporting regulatory filings and product understanding (06:56) Jitendra Kumar's career journey: from agricultural research in India to protein science and neurodegeneration, and how these experiences inform current PLV technology development (09:00) Challenges of early diagnostics and product development in neurodegenerative diseases (14:29) Decision-making differences and focus in academic versus industry biotech research (15:32) Practical advice on the importance of honest technology assessment, building networks, and understanding both strengths and weaknesses (16:16) Smart insight: A persistent challenge for groundbreaking delivery systems is the lack of established regulatory playbooks. Jitendra Kumar laid out a science-first approach: let data do the talking, supported by rigorous GLP toxicology studies and transparent communication with agencies. Regulatory bodies like Health Canada are receptive to innovation, provided that sponsors demonstrate safety, efficacy, and scientific rationale for any deviation from standard criteria. If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper: Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville Connect with Jitendra Kumar: LinkedIn: www.linkedin.com/in/jkumar2 Email: jitendra.kumar@entospharma.com Website: www.entospharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all? Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does. Key topics discussed: Jitendra’s career background in structural biology and journey to Entos Pharmaceuticals (03:18) The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55) Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27) The FAST protein platform: origins, function, and advantages for drug delivery (07:56) Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55) Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21) Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23) Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12) Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31) Balancing process robustness with speed in new biotech ventures (16:02) The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15) Smart insight: Jitendra’s takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both. If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper: Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville Connect with Jitendra Kumar: LinkedIn: www.linkedin.com/in/jkumar2 Email: jitendra.kumar@entospharma.com Website: www.entospharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could democratize access to advanced therapies and open entirely new doors for oral, topical, and even global vaccine delivery. This week, David Brühlmann welcomes Christopher Locher, CEO and Co-founder of Versatope Therapeutics. Christopher has shaped the translation of novel vesicle technology from idea to clinical pipeline, navigating both the science and the unstructured realm of first-in-class GMP manufacturing. Topics discussed: Tackling GMP manufacturing challenges and analytics development from scratch (00:34) Deciding what to outsource vs. insource as a small biotech, and the value of a robust tech transfer process (02:25) Perspectives on partnering with CDMOs versus managing manufacturing and analytics in-house (02:40) Geographic expansion goals and considerations for delivering low-cost biologics in underserved markets (04:26) Differentiators of Versatope’s platform—endotoxin-free processes and non-pathogenic strains (05:05) Key advice on critical quality attributes and early regulatory planning for Phase 1 readiness (06:19) Lessons learned as a biotech founder—getting support, leveraging networks, and planning cost-effectively (07:57) Understanding end users, leveraging I-Corps™, and customer discovery in early product development (09:04) The science and promise of engineered nanovesicles: delivery routes, biological origins, and research applications (10:12) Business models for platform out-licensing and potential for co-development partnerships (12:58) Practical takeaways for scientists: setting "good enough" standards and focusing on lean, regulatory-aligned development (13:28) Smart insight: Christopher is honest about his blind spots, learning on the fly from CMC consultants, and the practical importance of “good enough” regulatory solutions delivers sharp advice for anyone charting the long road from discovery to human trials. Think monoclonal analytics, batch consistency, and the art of prioritization, all from someone who’s made it work with a small team and limited resources If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients. Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal Connect with Christopher Locher: Website: www.versatope.com LinkedIn: www.linkedin.com/in/christopher-locher-biotech Support the show

What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines? While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice. Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation. Topics discussed: How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39) The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17) Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38) Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28) Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53) Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47) Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21) Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53) Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30) The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12) Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech. If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients. Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal Connect with Christopher Locher: Website: www.versatope.com LinkedIn: www.linkedin.com/in/christopher-locher-biotech Support the show

How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts. Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning. Topics covered: Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35) Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07) Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34) Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42) Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26) The importance of understanding basic statistics before relying on AI-generated models (15:22) A stepwise summary for deploying digital modeling effectively in biotech (16:01) Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number. Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny. Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy Connect with Ignasi Bofarull-Manzano: LinkedIn: www.linkedin.com/in/ignasi-bofarull Körber Pharma website: www.koerber-pharma.com Support the show

Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files, historians and ELNs is probably enough to start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, breaks down what a digital twin actually is, where modeling pays back fastest across the product lifecycle, and how to tell a real business case from an expensive proof of concept. In this episode: Misconceptions about data requirements for digital twins—why quality and context of data matter more than sheer quantity (02:40) Ignasi’s journey from curiosity in biology to a career in data science, modeling, and digital twins (04:31) Clear distinctions between digital models, digital shadows, and digital twins, explained with real-world analogies (06:42) How to approach digital development when faced with legacy data silos and scattered analytics (09:56) The importance of starting with a focused business need instead of chasing trends or buzzwords (12:28) Insights into where modeling truly delivers value in the product lifecycle—development versus manufacturing (13:11) Strategies for small companies to leverage digitalization and data from the ground up (15:56) An accessible overview of physics-informed AI, physical AI, and hybrid modeling—and their application in bioprocessing (18:15) The comparative advantages of physics-informed AI versus hybrid models in different bioprocessing contexts (24:45) Smart insight: Do not start with the model. Start with the bottleneck. Identify the business need first, then the decision the model must support, then the minimum data required for that context of use. Build the model offline, concatenate it end to end across unit operations rather than optimizing one in isolation, and prove the value before connecting a single interface. Teams that skip this sequence end up building models because models sound impressive, and those projects get expensive before they get useful. Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny. Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy Connect with Ignasi Bofarull-Manzano: LinkedIn: www.linkedin.com/in/ignasi-bofarull Körber Pharma website: www.koerber-pharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

How do you turn a lab-born regenerative medical device into a solution that surgeons actually want to use and investors want to back? The path from academic innovation to clinical adoption is full of practical hurdles and strategic pivots, where compelling science alone isn’t enough. David Brühlmann welcomes back Eva-Maria Balet, whose journey spans tissue engineering research at EPFL to leading Regenosca through first-in-human trials, fundraising, and an executive MBA completed while running the company. This conversation covers the practical realities behind that journey, from quality control to clinical setbacks to investor pitches. Topics discussed: Defining TissueSpan’s regulatory path and quality control as a medical device (02:49) The significance of first-in-human studies and what early clinical experience reveals (04:11) Selecting an initial clinical indication and opportunities for technology expansion (05:50) Realistic assessment of where soft tissue repair technologies apply—and where they do not (07:18) The stepwise progression from in vitro to animal models in product development (08:18) Navigating setbacks, including the impact of Covid-19 on clinical trials, and the value of adaptability (10:36) Bridging science and business in biotech fundraising and communication (12:15) Key takeaways from pursuing an executive MBA alongside building a biotech company (13:42) The importance of collaboration, mindset, and meaningful networks in driving biotech innovation (15:19) Smart insight: The transition from scientist to founder brought its own learning curve. Eva-Maria pursued an executive MBA while running Regenosca, and points to financial and business vocabulary as the skill she'd have built earlier if she could. For a technical founder or CMC lead, the lesson isn't to become a business generalist, it's that the moment you're translating a manufacturing process or clinical dataset into an investor pitch, fluency in the language of accounting, market strategy, and cost structure becomes as load-bearing as the science itself. This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery. Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho Connect with Eva-Maria Balet: LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737 Regenosca website: www.regenosca.com Support the show

Imagine a wound too large for the body to close on its own. That's the problem Eva-Maria Balet set out to solve, not with living cells, but with a structural bridge that lets the body's own healing mechanisms do the rest. In this episode, David Brühlmann welcomes Eva-Maria Balet, Co-Founder & CEO of Regenosca. Trained at EPFL, Eva-Maria brought her fascination with cellular "factories" from academia straight into entrepreneurship. Rather than chasing elegant science for its own sake, she built her company around a single principle: start with a real clinical need and build backward, collaborating with clinicians from day one so every experiment serves a patient. Highlights & Topics: Why starting with clinical needs—not just scientific excitement—creates meaningful real-world impact in life sciences (02:38) How Eva-Maria’s fascination with biotechnology guided her from cell factories to developing scaffolds for tissue repair (03:51) The unmet challenges in current soft tissue repair treatments and where new solutions are needed (05:51) What makes Regenosca’s fully-engineered collagen implant, TissueSpan, different from existing meshes and biological materials (07:09) The biological mechanisms behind tissue regeneration using a temporary collagen scaffold (08:28) Translating lab-scale research into a robust, scalable, and regulatory-compliant production process (10:34) The practical realities and hurdles of navigating the medical device vs. biologic regulatory pathways (11:59) Advice on building regulatory expertise into your founding team or leveraging consultants effectively (13:31) The importance of interdisciplinary teams and trust when forming biotech startups (14:36) Smart insight: Eva-Maria put it plainly: what works in the lab has to work reliably every single time you produce it for a patient. That shift, from proving a concept to controlling a process, from raw materials through in-process controls to final product testing, is the same discipline any CMC scientist recognizes: science alone doesn't get a product to patients. Reproducibility does. This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery. Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho Connect with Eva-Maria Balet: LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737 Regenosca website: www.regenosca.com Support the show

Building a cell therapy company is hard. Building a genetically engineered iPSC therapy for the brain, on a preclinical budget, is one of the hardest translational problems in biotech. Every experiment has to move the program closer to an IND, or it's motion without progress. That's the operating constraint Bilal Fares faces as CEO and co-founder of AzureCell, the University of Geneva spin-off engineering neuroprotective iPSC neurons for Parkinson's disease. In Part 2, he walks through how his team decides what to build, where AI and synthetic biology genuinely accelerate a CMC roadmap, and the four founder lessons he wishes he'd internalized earlier, including his conviction that scientists who use AI will replace those who don't. Topics discussed include: Strategies for prioritizing experiments and narrowing focus with limited resources (03:33) How business opportunity validation programs helped define a product roadmap (04:08) Integrating AI and synthetic biology into research programs—and where these tools do, and don’t, accelerate development (05:07) Building a cell therapy platform for personalized approaches in neurological diseases beyond Parkinson’s (06:38) Lessons learned in biotech leadership and why tackling big problems matters (08:08) Key advice for aspiring biotech entrepreneurs: kill your own solutions quickly, and learn from others (09:27) The importance of having a strong team and how a powerful mission attracts top talent (12:21) AzureCell’s near-term plans and future goals, including upcoming fundraising and R&D milestones (13:30) Smart insight: What separates successful biotech ventures from the rest? According to Bilal Fares, it is not just technical skill but mindset. First, choose a problem large enough to be worth the struggle. Second, try to “kill your solution as fast as possible”—engage experts, enter competitions, and seek brutal feedback early so you can pivot, improve, or abandon as needed. And finally, plan with the end (approval, patients, impact) always in sight. If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities. Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee Episodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Connect with Bilal Fares: LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: info@azurecell.co Support the show

Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today. Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them. Topics discussed: Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06) Bilal’s personal story and the events that guided his commitment to Parkinson’s research and entrepreneurship (04:03) How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05) The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson’s disease mechanisms (11:31) The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38) Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26) The current status of Azure’s preclinical and manufacturing development, and their plans for clinical translation (14:31) Why previous therapies for Parkinson’s have fallen short, and how cell therapy might sidestep these limitations (15:57) The potential and challenges of using cell therapy for other brain diseases like Alzheimer’s (18:26) Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures. If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities. Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee Episodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Connect with Bilal Fares: LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: info@azurecell.co Support the show

How much of your research lives and dies on the bench? Not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle. Jan Hunik and Matt Baker from MosaMatrix discuss the practical challenges and lessons learned from spinning out a biomaterials company from academia. They explore the importance of quality standards in biotech startups, building a team with complementary skills, and the realities of developing reproducible 3D culture systems for modern research. Topics discussed: The critical gap between invention and reliable biomaterial products (00:40) Building company culture around quality standards from day one (02:45) Balancing scientific curiosity and business direction as co-founders (03:51) The impact of university partnerships on early-stage company development (06:02) Funding challenges and strategies for sustaining a biotech startup (06:47) Advice for scientists on addressing real market needs versus pushing technology (07:50) The importance of listening to customers and investors to find product-market fit (09:19) Vision for scaling technology and breaking even in the next two to three years (10:06) New frontiers in engineering living materials and animal-free biomaterials (12:04) Smart insight: The MosaMatrix team believes good materials are key to unlocking advances in drug discovery, cellular agriculture, and engineered living materials. Their story is a testament to how integrating rigorous science, business discipline, and a razor focus on real-world needs can create the foundation for lasting innovation in biotech. If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles. Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang Connect with Jan Hunik and Matt Baker: Emails: matt.baker@mosamatrix.com and jan.hunik@mosamatrix.com Website: www.mosamatrix.com LinkedIn Jan Hunik: www.linkedin.com/in/jan-hunik-0183734 LinkedIn Matt Baker: www.linkedin.com/in/matthew-baker-0abb981b Support the show

What if the real obstacle in 3D cell culture and tissue engineering isn't the cells, but the very ground they grow on? For years, cell culture has relied on flat plastic and passive scaffolds. But biology doesn't happen on a petri dish—cells live in three dimensions, surrounded by a dynamic environment that talks back, adapts, and shapes development in ways static gels simply cannot. That's the premise behind MosaMatrix, a novel hydrogel platform designed to transform how we grow cells, engineer tissues, and screen new drugs created by CEO Jan Hunik and CTO Matt Baker. Topics discussed: Why traditional flat, 2D cell culture misses the biological mark and what a responsive cell environment really looks like (00:27) The origins of MosaMatrix and the realization that new, adaptive hydrogels were needed for dynamic cell culture (04:45) What makes the MosaMatrix hydrogel different—and why passive scaffolds fall short (06:12) Mechanical and biological characteristics that define hydrogel performance, from stiffness to stress relaxation (07:48) The company's pivot from 3D tissue printing to focusing on high-throughput 3D cell culture for drug discovery (08:42) Advantages of a non-animal-derived, reproducible matrix for research and industry (10:20) Strategies for obtaining real-world customer feedback and working in consortia with academia and industry partners (11:51) Key hurdles in quality control, reproducibility, and measuring success in the emerging field (16:05) Challenges with standardizing organoids and the move to smaller, more automatable culture systems (17:50) The impact of automation and data consistency for scaling up 3D cell culture (18:14) Smart insight: MosaMatrix validates its hydrogel not through internal R&D alone, but through direct collaboration with academic and industry partners — testing performance across cell types and culture media. This includes a ~50-company consortium building next-gen 3D cell culture tools and a new consortium improving kidney dialysis with living human cells. The partnerships surface real variables, like how much culture media composition affects results, that continually shape product development. If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles. Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang Connect with Jan Hunik and Matt Baker: Emails: matt.baker@mosamatrix.com and jan.hunik@mosamatrix.com Website: www.mosamatrix.com LinkedIn Jan Hunik: www.linkedin.com/in/jan-hunik-0183734 LinkedIn Matt Baker: www.linkedin.com/in/matthew-baker-0abb981b Support the show

In the biotech industry, advancing cell-based therapies is not just about innovation. It's about solving real gaps where conventional treatments fall short, especially against complex, aggressive tumors. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann welcomes Jun Yung Woo, Co-Founder of AGEM Bio, who offers an in-depth look at the science and strategy behind engineered mesenchymal stem cells (MSCs), with a focus on why glioblastoma is the right proving ground for the platform. Topics discussed: Why glioblastoma is the right Phase I indication: infiltrative growth, immunosuppression, and STING pathway deficiencies that make GBM uniquely suited to the platform (02:43) The surgical workflow: intracavity MSC delivery during tumor resection, oral 5-FC administration, and how engineered cells act as local bioreactors in the resection cavity (04:05) Mechanisms by which engineered MSCs target heterogeneous and invasive tumors through shared vulnerabilities rather than antigen recognition (05:58) Overcoming immune rejection with allogeneic therapies and the unique immunological profile of MSCs (07:32) Manufacturing and scale-up: addressing donor variability, GMP production, and building a reproducible process (09:16) Why GMP manufacturing should be designed in from the earliest stages of research (10:50) Beyond glioblastoma: expanding the platform to other solid tumors, regenerative medicine, and chronic inflammatory disease (11:27) Strategies for international trial expansion and partnerships beyond Singapore (12:41) Reframing MSCs from stem cell therapy to programmable delivery platform: the MSC 2.0 thesis (14:10) Smart insight: The shift Jun Yung articulates is from treating stem cells as the therapy to treating them as programmable therapeutic vehicles. Once you can reliably engineer, manufacture, and preserve their function, the limitation is no longer what the cell naturally does. It becomes what biology you can encode into it. Glioblastoma is the proving ground, and the platform's reach extends to liver cancers, sarcomas, peritoneal malignancies, and chronic inflammatory disease. These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies: Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster Connect with Jun Yung Woo: LinkedIn: www.linkedin.com/in/junyungwoo AGEM Bio website: www.agem.bio Email: yung@agem.bio Support the show

What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do For years, mesenchymal stem cells (MSCs) have turned heads for their ability to home in on damaged tissue, yet their clinical utility has lagged behind the hype. What would it take to transform MSCs from passive healers into precision vehicles for next-generation cancer treatment? This week, David Brühlmann sits down with Jun Yung Woo, Co-Founder of AGEM Bio, who’s devoted nearly two decades to decoding and reimagining the potential of MSCs. From engineering stress-resilient cells to pioneering dual-payload therapeutic platforms, Jun Yung Woo bridges fundamental biology and real-world clinical translation. Topics discussed: The case for understanding cell biology before focusing on process scale-up in bioprocessing (02:38) Jun Yung Woo's personal and scientific journey toward developing engineered MSC therapeutics (04:36) How MSCs sense their environment and exert therapeutic effects via secreted factors, rather than tissue replacement (08:28) Key differences between MSC therapies and immune cell therapies like CAR T cells (10:35) Overview of non-viral engineering platforms, and the importance of intracellular trafficking for modifying MSCs (12:23) Design of AGEM Bio's dual-payload MSC product (cytosine deaminase and interferon beta) to induce highly localized tumor stress and immune activation (14:10) Strategies for controlling MSC targeting and minimizing off-target effects, including the use of prodrug activation and localized cell delivery (17:23) Study results from treating companion animals with engineered MSCs, and observations of tumor regression and possible signs of immune memory (20:29) Open questions about the durability of antitumor responses and future directions for clinical research (22:34) Smart insight: Jun Yung Woo challenges the rush toward bioprocess scale-up, arguing that a deeper understanding of cellular biology should come before manufacturing cells at scale. This episode explores how scaling the wrong biology can derail entire therapeutic platforms—and why aligning process development with cellular function may be critical for clinical success. These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies: Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster Connect with Jun Yung Woo: LinkedIn: www.linkedin.com/in/junyungwoo AGEM Bio website: www.agem.bio Email: yung@agem.bio Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show